ClinicalTrials.gg
CompletedNCT00439283Updated Feb 27, 2007

Study of Two Schedules of Infliximab Maintenance Therapy in Ankylosing Spondylitis

A Phase 3 interventional study of infliximab and methotrexate in Ankylosing Spondylitis, sponsored by Association de Recherche Clinique en Rhumatologie. Completed at 31 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-02-27.

Sponsored by Association de Recherche Clinique en Rhumatologie · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies testing infliximab in Spondylitis, Ankylosing — 1 open to participants now, 1 under way, none of them phase 3. Infliximab · Spondylitis, Ankylosing.

Enrollment
4th of 20
240 · median 85
Started
2003
the only one that year
Phase 3
5 of 20
none open now
Registered
4th of 20
by date
Lead sponsor
1 of 20
Association de Recherche Clinique en Rhumatologie

Among the 20 studies testing infliximab in Spondylitis, Ankylosing, this one is the 4th largest by enrollment, is the only one that started in 2003, is one of 5 in phase 3, and was the 4th registered.

Spondylitis, Ankylosing

535 studies on the registry are indexed under Spondylitis, Ankylosing; 100 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

1 of the 20 studies testing infliximab in Spondylitis, Ankylosing is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About infliximab

Infliximab: first FDA approval 1998 (REMICADE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 24 (38%) set no upper age limit and 33 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing infliximab in Spondylitis, Ankylosing, or all of them as a file.
02

Study summary

Continuous treatment with the anti-tumor necrosis factor alpha monoclonal antibody infliximab is efficacious in ankylosing spondylitis (AS), whereas treatment discontinuation results in disease relapse, with variable delay. Objective of this study was to compare efficacy between a continuous treatment with infliximab, and a treatment adapted to symptoms recurrence. Addition of methotrexate (MTX)to infliximab was also tested.

Read the detailed description

Patients with active AS were randomly assigned to receive infliximab every 6 weeks (Q6), or only upon symptoms recurrence (on-demand), following a loading regimen of infusions at weeks 0, 2, and 6. Patients in the latter group were randomly assigned to receive MTX or not, starting 4 weeks prior to infliximab. Monitoring was performed over one year. The primary end point was the proportion of patients with a 20% improvement response according to the ASsessment in Ankylosing Spondylitis (ASAS) criteria, at week 54.

03

Conditions studied

  • Ankylosing Spondylitis

Keywords

  • Ankylosing spondylitis
  • infliximab
  • Systematic regimen
  • On-demand regimen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (> 18 years old)
  • With a diagnosis of AS
  • With at least one of the following evidences for active inflammation, present within 3 months before inclusion: a serum C-reactive protein (CRP) level above twice the upper limit value of the normal range, a positive magnetic resonance imaging of the spine or sacro-iliac joints, a vascularized enthesitis by power-Doppler ultrasound technic.
  • Presence of clinically active axial disease, as defined by 1) a Bath AS Disease Activity Index (BASDAI) (18) of ≥ 3/10, and 2) a score of ≥ 3/10 for axial pain (second item of BASDAI).
  • Disease-modifying antirheumatic drugs (DMARDs), such as sulphasalazine, methotrexate, hydroxychloroquine, intra-muscular gold, thiol compound, cyclosporin, intravenous biphosphonate had to be discontinued for at least 4 weeks before inclusion.
  • Dosages of NSAIDs and were required to remain stable for at least 4 weeks before inclusion.
  • A negative pregnancy test result was required for non menopausal female patients, and during the study period and for six months after the last infusion of infliximab was recommended to all patients of .

Exclusion criteria

Exclusion Criteria:

  • Pregnancy.
  • Breastfeeding.
  • Vaccination with a live organism during the last month.
  • Present infection or any episode of serious infection within the last three months.
  • Active within the previous five years.
  • Alcohol or drug addiction.
  • Severe chronic concomitant disease.
  • Administration of an drug within the last three months, or of any known TNF inhibitor therapy in the past (such as thalidomide, infliximab or etanercept).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The primary end point was the proportion of patients with a 20% improvement response according to the ASAS criteria, at week 54.

Secondary outcomes

  1. Achievement of the ASAS50 and ASAS70.

  2. The proportion of patients who experienced a partial remission, according to ASAS definition.

  3. Improvement in independent components of the ASAS response criteria.

  4. BASDAI.

  5. SF-36.

  6. Schober test.

  7. Finger to floor test.

  8. Chest expansion score.

  9. Occiput-to-wall measurements.

  10. Acute-phase reactants (erythrocyte sedimentation rate and C-reactive protein level).

  11. Number of infusions administered after the loading regimen.

  12. Number of patients requiring an increase in the dose of infliximab.

  13. The area under the curves (AUCs) of the BASDAI recorded on a weekly basis on automatic phone server, calculated from week 0 through week 54.

  14. The area under the curves (AUCs) of the global pain scores recorded on a weekly basis on automatic phone server, calculated from week 0 through week 54.

07

Study locations

31 sites
  • CHU Amiens
    Amiens, 80054, France
  • CHU Hôpital Minjoz
    Besançon, 25030, France
  • Hôpital Avicenne
    Bobigny, 93009, France
  • Hôpital Pellegrin
    Bordeaux, 33076, France
  • Hôpital Ambroise Paré
    Boulogne Billancourt, 92104, France
  • CHU de la Cavale Blanche
    Brest, 29609, France
  • CHU Côte de Nacre
    Caen, 14033, France
  • Hôpital Gilles de Corbeil
    Corbeil Essonnes, 91106, France
  • Hôpital Henri Mondor
    Creteil, 94010, France
  • Hôpital Général
    Dijon, 21000, France
  • CHU A. Michallon
    Grenoble, 38043, France
  • Groupe Hospitalier du Havre
    Le Havre, 76083, France
  • Hôpital Bicêtre
    Le Kremlin Bicêtre, 94275, France
  • CHRU Hôpital Roger Salengro
    Lille, 59037, France
  • CHU Dupuytren
    Limoges, 87042, France
  • Centre Hospitalier Saint Philibert
    Lomme, 59160, France
  • CH St Joseph - St Luc
    Lyon, 69365, France
  • Hôpital de la Conception
    Marseille, 13385, France
  • Hôpital Lapeyronie
    Montpellier, 34295, France
  • CHU l'Archet 1
    Nice, 06202, France
  • Hôpital Porte Madeleine
    Orléans, 45032, France
  • Hôpital de la Pitié
    Paris, 75013, France
  • Hôpital Cochin
    Paris, 75014, France
  • CHU de Poitiers
    Poitiers, 86021, France
  • CHU - Hôpital Sud
    Rennes, 35056, France
  • CHU - Hôpital de Bois Guillaume
    Rouen, 76031, France
  • CHU Saint-Etienne
    Saint-Etienne, 42055, France
  • CHU Hautepierre
    Strasbourg, 67098, France
  • Hôpital de Purpan
    Toulouse, 31059, France
  • CHU Hôpital Trousseau
    Tours, 37044, France
  • CHU Nancy-Brabois
    Vandoeuvre Les Nancy, 54511, France
08

References and documents

Publications

  • Fautrel B, Benhamou M, Breban M, Roy C, Lenoir C, Trape G, Baleydier A, Ravaud P, Dougados M. Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial. Ann Rheum Dis. 2010 Feb;69(2):424-7. doi: 10.1136/ard.2008.103887. Epub 2009 Sep 9. PubMed 19740900 ↗
  • Breban M, Ravaud P, Claudepierre P, Baron G, Henry YD, Hudry C, Euller-Ziegler L, Pham T, Solau-Gervais E, Chary-Valckenaere I, Marcelli C, Perdriger A, Le Loet X, Wendling D, Fautrel B, Fournie B, Combe B, Gaudin P, Jousse S, Mariette X, Baleydier A, Trape G, Dougados M; French Ankylosing Spondylitis Infliximab Network. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum. 2008 Jan;58(1):88-97. doi: 10.1002/art.23167. PubMed 18163509 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2003 and a completion of Dec 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2007
First posted
Feb 23, 2007
Start
Apr 2003
Completion
Dec 2004
Last update
Feb 27, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Feb 27, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00439283
Lead sponsor
Association de Recherche Clinique en Rhumatologie
First posted
Feb 23, 2007
Start date
Apr 2003
Completion
Dec 2004
Last update
Feb 27, 2007

Study contacts

Maxime DOUGADOS, Professor
study director · ARCR

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Infliximab

Start the discussion